Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Imatinib

Imatinib Phase 2 (400 vs 600 mg)

Novartis · Phase 2 · Completed · Enrollment 147

Registry id n/r

ArmPopulationDoseEstimandComparatorEfficacy
Imatinib 400 mgKIT (CD117) positive unresectable or metastatic GIST400 mgITTimatinib 600 mgobjective response rate (SWOG): 68.5%, up to 36 months
Imatinib 600 mgKIT (CD117) positive unresectable or metastatic GIST600 mgITTimatinib 400 mgobjective response rate (SWOG): 67.6%, up to 36 months